SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
PR Newswire —
ROCKVILLE, Md. , Jan. 12, 2026 /PRNewswire/ -- SciNeuro grants Novartis an exclusive worldwide license to develop SciNeuro's novel antibody program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer's Disease SciNeuro and...